The US and Canada have healthcare, life science and medical device industries that are
complex and interconnected.
On March 6, President Donald Trump instituted a 25 percent ad valorem rate of duty on goods
imported from Canada under the International Emergency Economic Powers Act.[1] The
tariffs will not be implemented on goods that comply with the United States-MexicoCanada Agreement until April 2.[2] In turn, Canada has announced a $155 billion tariff
package on the US.[3]
Download the full Law360 article, "Mitigating Tariff Risks For Healthcare In US And Canada."